Academic Journal
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications
| العنوان: | Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications |
|---|---|
| المؤلفون: | Tan, K-B, Putti, T C |
| بيانات النشر: | BMJ Publishing Group Ltd |
| سنة النشر: | 2005 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Original articles |
| الوصف: | Background: Cyclooxygenase 2 (COX-2), an inducible prostaglandin synthase, participates in inflammatory and neoplastic processes. It is expressed by various tumours and contributes to carcinogenesis. Notably, COX-2 inhibitors appear to have tumour suppressor effects and are being evaluated in clinical trials. Aims: To investigate COX-2 expression in nasopharyngeal carcinoma (NPC), a common tumour in parts of Asia, and to discuss potential implications. Methods: Eighty five cases of NPC were reviewed. COX-2 immunohistochemistry and semiquantitative assessment of expression in nasopharyngeal biopsies were performed. Because COX-2 is proangiogenic, tumour microvessel density was also assessed with the use of CD31 immunohistochemistry. Results: Histologically, 78 NPCs were undifferentiated, six were non-keratinising, and one was keratinising. Thirty nine NPCs had adjacent dysplastic epithelium. COX-2 expression was noted in 60 NPCs, 14 of 39 samples of dysplastic epithelium, and only one of 25 samples of normal epithelium (p < 0.01). Microvessel density was not significantly different between COX-2 positive and COX-2 negative tumours (p = 0.774). Tumour COX-2 positivity was not associated with higher tumour stage (p = 0.423). Conclusion: COX-2 expression is more frequently seen as nasopharyngeal epithelium progresses from normal to dysplastic to carcinoma. This suggests that COX-2 contributes to the multistep process of NPC carcinogenesis. COX-2 represents a therapeutic target for COX-2 inhibitors, and there is thus a basis for the further investigation of this adjuvant treatment modality for NPC. COX-2 inhibitors are known to potentiate the antitumour effects of radiotherapy, which is the primary treatment for NPC. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://jcp.bmj.com/cgi/content/short/58/5/535; http://dx.doi.org/10.1136/jcp.2004.021923 |
| DOI: | 10.1136/jcp.2004.021923 |
| الاتاحة: | http://jcp.bmj.com/cgi/content/short/58/5/535 https://doi.org/10.1136/jcp.2004.021923 |
| Rights: | Copyright (C) 2005, BMJ Publishing Group |
| رقم الانضمام: | edsbas.36D61238 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/jcp.2004.021923 |
|---|